IHL News: Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (‘OSA’) - 18th Nov 2022, 12:00am

[annb0t]

Incannex Healthcare

Highlights:

Incannex has engaged CMAX Clinical Research and Novotech CRO to undertake a bioavailability/bioequivalence (‘BA/BE’) study to assess the pharmacokinetics and tolerability of IHL-42X in 116 participants Incannex is well progressed in drafting an Investigational New Drug (‘IND’) Application for submission to the US Food and Drug Administration (‘FDA’) in Q1 of 2023 Once the IND is open, Incannex will commence pivotal, multi-site Phase...

>>> Read more: Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (‘OSA’)